Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 24, 2015 - Issue 1
Submit an article Journal homepage
194
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluation

Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy

Giuseppe BronteUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Francesca Lo VulloUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Gianfranco PerniceUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Antonio GalvanoUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Eugenio FiorentinoUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Giuseppe CiceroUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Viviana BazanUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Palermo, Italy
,
Christian RolfoUniversity of Antwerp, University Hospital Antwerp, Oncology Department, Antwerp, Belgium
&
Antonio RussoUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Via del Vespro 129 - 90127 Palermo, Italy+ 39 091 6552500; + 39 091 6554529; [email protected]
, MD PhD (Professor) show all
Pages 125-132 | Published online: 03 Nov 2014

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Seiya Sato & Hiroaki Itamochi. (2016) Profile of farletuzumab and its potential in the treatment of solid tumors. OncoTargets and Therapy 9, pages 1181-1188.
Read now

Articles from other publishers (3)

A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. V. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O’Dwyer, A. P. Chen & K. T. Flaherty. (2022) Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. npj Precision Oncology 6:1.
Crossref
Luojun Chen, Min Peng, Na Li, Qibin Song, Yi Yao, Bin Xu, Huali Liu & Peng Ruan. (2018) Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer. Scientific Reports 8:1.
Crossref
Bert Müller & Marcel Van de VoordeJean‐Luc Coll & Jungyoon Choi. 2017. Nanoscience and Nanotechnology for Human Health. Nanoscience and Nanotechnology for Human Health 125 156 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.